Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues.
about
Modafinil as a catecholaminergic agent: empirical evidence and unanswered questionsPsychostimulants and cognition: a continuum of behavioral and cognitive activationPharmacological interventions for sleepiness and sleep disturbances caused by shift workDopamine transporter-related effects of modafinil in rhesus monkeys.Modafinil blocks reinstatement of extinguished opiate-seeking in rats: mediation by a glutamate mechanismR-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuseA practical guide to the therapy of narcolepsy and hypersomnia syndromesEffects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implicationsA review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescentsReview of pharmacological treatment in mood disorders and future directions for drug development.Agonist replacement for stimulant dependence: a review of clinical researchNew treatments for cocaine dependence: a focused reviewArmodafinil-induced wakefulness in animals with ventrolateral preoptic lesionsModafinil does not serve as a reinforcer in cocaine abusersPharmacological approaches to methamphetamine dependence: a focused review.A rare case modafinil dependence.A retrospective review of supratherapeutic modafinil exposures.Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendationsDependence on supratherapeutic doses of modafinil: a case reportThe neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.Modafinil attenuates disruptions in cognitive performance during simulated night-shift work.Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats.Use of modafinil for the treatment of attention deficit/hyperactivity disorder.Modafinil: a review of neurochemical actions and effects on cognition.Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys.Cognitive enhancement: methods, ethics, regulatory challenges.Modafinil for the treatment of methamphetamine dependenceModulation of fronto-cortical activity by modafinil: a functional imaging and fos study in the rat.Agonist replacement therapy for cocaine dependence: a translational review.Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction.Tick-borne bacterial, rickettsial, spirochetal, and protozoal infectious diseases in the United States: a comprehensive review.Evaluation of the safety of modafinil for treatment of excessive sleepinessProlonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons.Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders.Neuroprotective agents in schizophrenia and affective disorders.Ready for takeoff? A critical review of armodafinil and modafinil for the treatment of sleepiness associated with jet lag.A review of the effects of modafinil on cognition in schizophreniaExamining the Frequency of Stimulant Misuse among Patients with Primary Disorders of Hypersomnolence: A Retrospective Cohort StudyEffects of modafinil and R-modafinil on brain stimulation reward thresholds: implications for their use in the treatment of psychostimulant dependence.Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials.
P2860
Q21129426-D39D3E43-C74C-4FFD-A886-6F85FC441ADCQ22242285-3A32EE69-A6DC-47B5-96FA-D2C47639CDBBQ24194412-DBF3237B-66AD-48A1-BCC5-FB3B8C3DB369Q24608414-AA951F1E-C279-46B9-9307-04D0E809467DQ24608557-8B65C71A-2DA9-4F33-B8AA-610B566036F0Q24621917-8B2A5A49-8743-48DE-8E3F-EDF298590B7BQ24623713-792C09D4-A130-44AB-917A-C9DB1EC47CA1Q24645440-427B877F-D719-43EB-ABF7-E5000D750B54Q24658208-2F005509-2D4A-4988-8C67-F4C6006AEE8AQ26853509-3E3C51DD-743A-447A-8810-A9F6D15912E0Q27014854-37A944B9-E3D5-418C-9771-506055E9ADF9Q28252765-D3D76093-E2D4-46EF-9518-A81B69F6808BQ33583463-7A6D1F7C-5BBA-4CAC-9380-870AF4EF2B7BQ33744007-05A4F57B-C86A-472E-87FC-F129F7D0A943Q33906303-8DF5DA8F-A1FD-4F09-8651-6DAA76C529FEQ34043246-C63B65E3-DD82-47F6-85F9-F46F32884B98Q34089062-6BD4613C-BD1F-477E-8C80-16010352B9C8Q34225896-AEA8D6D9-9DF4-474D-8148-B592C032394CQ34331610-949B6E09-57EC-4FE4-BAF2-F4845F7010F0Q34363257-FED948C1-D114-43A2-ADDC-1E47D9F9FE61Q34482029-FF619561-D61C-4612-879A-7CF7EFDC9089Q34494307-A97CA6CC-5A2C-4803-BE1F-EF94EEE2317EQ34570619-287B9D8A-86ED-4726-BA21-EB832CC13648Q34665871-BA796B9D-1294-4C33-AC80-6B0F36AA9332Q34817123-16DAFB8C-3092-4E66-B04B-73E9B80369D1Q34988104-D8C85DA2-3893-4512-8BDB-F75DAE1B18EBQ35583271-80AA0D26-EE20-4229-92A0-75ECABB0EBDEQ35679970-D6D07298-137C-4DC7-85B7-E0B94C19AC9DQ35799846-AABFB556-C5A9-4B40-B5AA-4157F48B96E7Q35927738-310B6127-F3C5-4047-B812-5985A652337FQ36070925-3B885685-DC7D-4636-8DBA-0E7FBC6DA744Q36099680-D93DE8DA-9E82-4052-A0E7-7C4CAFB042A3Q36183647-470790AD-2FE9-42A7-B554-6ECAE0022C5CQ36453288-A2246394-028E-47AC-A209-7974A53F85E4Q36458436-3B9E826D-D6FE-4E5F-855B-D3086DC964C9Q36779795-BCAD50CE-610F-42D3-AD69-8D02B4320F40Q36883313-89D8EA26-6F0B-4E66-9C13-0A85BFE3101AQ36897048-A4AB52F7-3513-4BFF-B4C8-4247301DB906Q36977149-B704063C-E20F-42F3-A2B1-5AF90418A83EQ37010436-FA3AD6BB-FC71-442D-A1E9-51995ADE7297
P2860
Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Modafinil: preclinical, clinic ...... iew of abuse liability issues.
@ast
Modafinil: preclinical, clinic ...... iew of abuse liability issues.
@en
type
label
Modafinil: preclinical, clinic ...... iew of abuse liability issues.
@ast
Modafinil: preclinical, clinic ...... iew of abuse liability issues.
@en
prefLabel
Modafinil: preclinical, clinic ...... iew of abuse liability issues.
@ast
Modafinil: preclinical, clinic ...... iew of abuse liability issues.
@en
P1476
Modafinil: preclinical, clinic ...... view of abuse liability issues
@en
P2093
Hugh Myrick
Robert Malcolm
P304
P356
10.1080/10401230490453743
P577
2004-04-01T00:00:00Z